StockNews.com Initiates Coverage on RedHill Biopharma (NASDAQ:RDHL)

Research analysts at StockNews.com assumed coverage on shares of RedHill Biopharma (NASDAQ:RDHL) in a research report issued to clients and investors on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

RedHill Biopharma Price Performance

Shares of RDHL opened at $6.21 on Tuesday. RedHill Biopharma has a 12 month low of $6.00 and a 12 month high of $38.50. The stock’s 50-day moving average is $7.40 and its two-hundred day moving average is $84.12. The stock has a market cap of $7.96 million, a PE ratio of -0.62 and a beta of 3.65.

RedHill Biopharma Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.